Abstract
The emergence SARS-CoV-2 P.1 lineage has been coincidental with a rapid growth in hospitalization in the northern region of Brazil. An exponential growth of severe COVID-19 occurred in Rio Grande do Sul state, Southern Brazil in February-2021. Whole-genome sequencing revealed that the previously undetected P.1 lineage accounted for 88.9% of specimens collected from patients at a referral COVID-19 hospital. These findings raise concerns regarding a possible association between lineage P.1 and rapid growth in cases and hospitalizations.
Competing Interest Statement
APZ, AFM and ALB are research fellows of the National Council for Scientific and Technological Development-CNPq, Ministry of Science and Technology, Brazil. APZ has received a research grant from Pfizer not related to this work. All other authors have no conflict to declare.
Clinical Trial
Not applicable
Funding Statement
This study was funded by FAPERGS - 20/2551-0000265-9 and National Institute of Antimicrobial Resistance Research - INPRA MCTI/CNPq/CAPES/FAPs n #16/2014. PLW and FCZV were supported by a grant from the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior CAPES.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Ethics Committees from Hospital de Clinicas de Porto Alegre, CAAE 30767420.2.0000.5327.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
